GKB Ophthalmics Intrinsic Value
GKB Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹168.69 | ₹134.95 - ₹202.43 | +200.0% | EPS: ₹12.68, Sector P/E: 22x |
| Book Value Method | asset | ₹140.57 | ₹126.51 - ₹154.63 | +150.0% | Book Value/Share: ₹112.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹112.46 | ₹101.21 - ₹123.71 | +100.0% | Revenue/Share: ₹248.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹112.46 | ₹101.21 - ₹123.71 | +100.0% | EBITDA: ₹12.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹74.27 | ₹59.42 - ₹89.12 | +32.1% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹81.15 | ₹73.04 - ₹89.27 | +44.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹168.69 | ₹151.82 - ₹185.56 | +200.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹112.46 | ₹101.21 - ₹123.71 | +100.0% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹168.69 | ₹151.82 - ₹185.56 | +200.0% | EPS: ₹12.68, BVPS: ₹112.00 |
Want to compare with current market value? Check GKB share price latest .
Valuation Comparison Chart
GKB Intrinsic Value Analysis
What is the intrinsic value of GKB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of GKB Ophthalmics (GKB) is ₹112.46 (median value). With the current market price of ₹56.23, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹74.27 to ₹168.69, indicating ₹74.27 - ₹168.69.
Is GKB undervalued or overvalued?
Based on our multi-method analysis, GKB Ophthalmics (GKB) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 16.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 10.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.99x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for GKB Ophthalmics
Additional stock information and data for GKB
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹7 Cr | ₹-2 Cr | Positive Operating Cash Flow | 6/10 |